local_hospital
verifiedVerified

Vitamed Galaj I Cichomski Sp. j.

Address
lock Available on a paid plan

Gastroenterology and Digestive Health

At Vitamed Galaj I Cichomski Sp. j. in Bydgoszcz, clinical research in gastroenterology focuses on digestive system diseases and related physiological processes, especially ulcerative colitis and eosinophilic esophagitis. These studies are designed to evaluate new treatments, improve long-term disease control, and better understand how therapies support patients living with chronic inflammatory conditions.

  • Moderately to severely active ulcerative colitis
  • Eosinophilic esophagitis
  • Evaluation of treatment effectiveness and long-term safety

The site contributes to research aimed at improving symptom control, maintaining remission, and expanding options for patients with ongoing gastrointestinal inflammation.

Respiratory and Pulmonary Diseases

A major part of the trial portfolio at this Polish site covers respiratory tract diseases, with emphasis on idiopathic pulmonary fibrosis, progressive pulmonary fibrosis, asthma, and other chronic lung conditions. The studies are exploring whether new therapies can preserve lung function, reduce disease progression, and improve day-to-day breathing outcomes.

  • Idiopathic pulmonary fibrosis and progressive pulmonary fibrosis
  • Asthma and chronic cough
  • Testing new treatments and assessing lung function benefits

This research also includes work in interstitial lung diseases and pulmonary sarcoidosis, reflecting a strong focus on difficult-to-treat respiratory disorders.

Neurology and Brain Health

The site is also involved in nervous system diseases, including migraine, multiple sclerosis, Parkinson’s disease, Alzheimer’s disease, and rare seizure disorders. These trials are generally intended to evaluate symptom relief, disease progression, and the longer-term safety of emerging therapies.

  • Migraine prevention and acute treatment
  • Multiple sclerosis and Parkinson’s disease
  • Alzheimer’s disease and rare epilepsy syndromes

Research in this area supports efforts to improve quality of life for people with chronic and often progressive neurological conditions.

Skin, Allergy, and Immune-Mediated Conditions

Clinical trials at Vitamed Galaj I Cichomski Sp. j. also address skin and connective tissue diseases and immune system diseases, including acne vulgaris, atopic dermatitis, and plaque psoriasis. The main goal is to test new therapies and assess whether they can provide better control of inflammatory skin symptoms with acceptable safety.

  • Acne vulgaris
  • Atopic dermatitis and plaque psoriasis
  • Evaluating safety, tolerability, and clinical benefit

This area of research reflects a broader interest in immune-driven conditions that affect both comfort and quality of life.

Cardiovascular and Musculoskeletal Research

The trial portfolio includes studies in cardiovascular diseases and musculoskeletal diseases, such as recent myocardial infarction with iron deficiency and knee osteoarthritis. These trials aim to determine whether new or repurposed treatments can improve recovery, reduce complications, and support physical function.

  • Recent myocardial infarction with iron deficiency
  • Mild non-serious osteoarthritis of the knee
  • Assessing recovery, mobility, and quality of life

The studies highlight an interest in both post-event cardiovascular care and symptom management for common joint disease.

Infectious Disease and Vaccine Research

Another research theme at the site involves bacterial infections and mycoses, with studies related to meningococcal infection and respiratory tract infections. These trials focus on vaccine effectiveness and prevention strategies, aiming to strengthen protection against infectious disease in children and healthy volunteers.

  • Meningococcal vaccination research
  • Prevention of respiratory tract infections in children
  • Evaluating immune response and protective benefit

This work supports public health efforts by studying how well preventive approaches can reduce infection risk across different age groups.

Site Overview

assignment
44
connected trials
corporate_fare
29
sponsors
science
60
IMPs

Activity Indicator

Last 6 months

3
Trials started
0% vs previous period.
3
Trials started 6–12 months ago
44
Total trials linked
Highly Active
trending_flatStable0%
1
1
1
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status

Top 5 of 10 therapeutic areas and 15 of 60 IMPs, ranked by number of trials.

lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years

Top 40 of 57 compounds, ranked by number of trials.

lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
14
Sponsors (total)
29
Active sponsors
12

Sponsor Network

Top 12 by active trials.

lock +11 more on a paid plan

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

lock +5 more on a paid plan

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 1 624 other sites in Poland

description
Trial volume
44
Outperforms 94% of sites
public
Therapeutic diversity
10areas
Outperforms 95% of sites
groups
Sponsor diversity
29sponsors
Outperforms 95% of sites

Therapeutic Area Benchmark — Poland

Select a therapeutic area to compare against other sites in Poland.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Poland

Market Share

Country: Poland

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Vitamed Galaj I Cichomski Sp. j.

lock Showing 1 of 44 trials — the rest is available on a paid plan.

IMP list

lock Showing 1 of 60 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
ADMILPARANT3Unknown2024-06-242024-07-15

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.